Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | CCR5 | P51681 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | HPD | P32754 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.39 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.39 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884770 | 0.85 | MAOB (0.45) | MAOBMAOACCR5LMNASMN1; SMN2 | |
| SCHEMBL2889943 | 0.83 | CCR5 (0.44) | MAOBMAOACCR5SMN1; SMN2NPC1 | |
| SCHEMBL2889904 | 0.82 | MAOB (0.42) | MAOBMAOACCR5LMNAMAPT | |
| SCHEMBL2888586 | 0.74 | MAPT (0.49) | MAOBMAOACCR5MAPTTDP1 | |
| SCHEMBL13384688 | 0.72 | HTR2A (0.46) | MAOBMAOALMNASTAT3SMN1; SMN2 | |
| SCHEMBL30866196 | 0.72 | MEN1 (0.68) | MAOBCCR5STAT3SMN1; SMN2PTGDR2 | |
| SCHEMBL29186218 | 0.72 | MEN1 (0.68) | MAOBCCR5STAT3SMN1; SMN2PTGDR2 | |
| SCHEMBL3290684 | 0.71 | CHRNA7 (0.40) | MAOBMAOASMN1; SMN2NPC1RAB9A | |
| SCHEMBL16064489 | 0.71 | USP28 (0.57) | MAOBCCR5LMNASMN1; SMN2HTT | |
| SCHEMBL4680227 | 0.71 | USP28 (0.68) | CCR5LMNASMN1; SMN2PTGDR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705043-B2 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-27 | — | — | US | disclosed |
| US-7705043-B2 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-27 | — | — | US | disclosed |
| US-7705043-B2 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-27 | — | — | US | disclosed |
| US-20070179139-A1 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2007-08-02 | — | — | US | disclosed |
| US-20070179139-A1 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2007-08-02 | — | — | US | disclosed |
| US-20070179139-A1 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2007-08-02 | — | — | US | disclosed |
| US-20040082798-A1 | Novel amino dicarboxylic acid derivatives with pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-04-29 | — | — | US | disclosed |
| EP-1368335-A2 | NOVEL AMINO DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | Bayer Aktiengesellschaft (DE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002070510-A2 | AMINO DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082798-A1 | Novel amino dicarboxylic acid derivatives with pharmaceutical properties | ABAT, BCAT2, GOT1 | MAOB 3358/4885MAOA 2829/4885CCR5 2730/4885 |
| US-20070179139-A1 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | ACMSD, AADAT, DDC | MAOB 924/4885MAOA 975/4885CCR5 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.